Ophirex
Latest round
- Series B
Last raised
- Mar 2022
Total raised
- $16M
Investors
- 1
About Ophirex
, operates as a biotechnology company. The company was founded by its CSO and President Matthew Lewin, and Jerry Harrison. In January 2023, Ophirex, Inc. As of 2022, the company’s CEO is Nancy J. Koch. Ophirex develops lifesaving antidotes like antivenom for the treatment of snakebites. The company offers Varespladib blocks secretory phospholipase-A2 (sPLA2), which is a drug that is used for the treatment of snakebites and other life-threatening bites and stings.
Who invested in Ophirex
1 investor across 1 round
See all investors in Ophirex
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Mar 16, 2022
Amount
$16M
Investors
Questions about Ophirex
Who invested in Ophirex?
Ophirex has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ophirex raised?
Ophirex has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ophirex last raise money?
Ophirex's most recent round on record is a Series B, in Mar 2022.
What does Ophirex do?
, operates as a biotechnology company.
Where is Ophirex headquartered?
Ophirex is headquartered in Corte Madera, US.
Which VCs invest in companies like Ophirex?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ophirex's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Ophirex? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.